Evidence map›Paper›PMID 26708575›Full record

ArticleInfectious diseases of poverty2015

Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty.

Ernest Tambo, Emad I M Khater, Jun-Hu Chen, Robert Bergquist, Xiao-Nong Zhou

Open access · goldAbstract readBiographyEditorialHistorical Article
In one paragraph

Article in Infectious diseases of poverty, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Five DifferentInternational journal of molecular sciences · 2023
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Antiviral and Immunomodulation Effects of Artemisia.Medicina (Kaunas, Lithuania) · 2021
    Review
  17. Caenorhabditis elegans in anthelmintic research - Old model, new perspectives.International journal for parasitology. Drugs and drug resistance · 2020
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 6 countries.

Ernest TamboDepartment of Biochemistry and Pharmaceutical Sciences, Higher Institute of Health Sciences, Université des Montagnes, Bangangté, Cameroon. tambo0711@gmail.com.
Emad I M KhaterPublic Health Pests Laboratory, Jeddah Municipality, Jeddah, Saudi Arabia.
Jun-Hu ChenNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai, 200025, P.R. China. junhuchen@hotmail.com.
Robert BergquistIngerod, Brastad, Sweden. robert.bergquist@yahoo.se.
Xiao-Nong ZhouPublic Health Pests Laboratory, Jeddah Municipality, Jeddah, Saudi Arabia. ipdzhouxn@sh163.net.
Ain Shams University · EGNational Institute for Parasitic Diseases · CNUniversity of the Witwatersrand · ZAYahoo (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to inflict a disproportionate global public health burden with associated consequences, thereby contributing to the vicious cycle of poverty and inequity. However, the effectiveness and large-scale coverage of artemisinin combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives. The paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the Nobel Prize in Physiology or Medicine in 2015. However, the story would not be complete without mentioning praziquantel. The huge contribution of this drug in modernizing the control of schistosomiasis and also some intestinal helminth infections had already shifted the focus from control to potential elimination of this disease. Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious diseases that humans have lived with since time immemorial. These drugs all have broad-spectrum effects, yet they are very safe and can even be packaged together in various combinations. The strong effect on so many of the great infectious scourges in the developing countries has not only had a remarkable influence on many endemic diseases, but also contributed to improving the cost structure of healthcare. Significant benefits include improved quality of preventive and curative medicine, promotion of community-based interventions, universal health coverage and the fostering of global partnerships. The laudable progress and benefits achieved are indispensable in championing, strengthening and moving forward elimination of the IDoPs. However, there is an urgent need for further innovative, contextual and integrated approaches along with the advent of the Sustainable Development Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.

Indexed as

Anti-Infective AgentsAntiprotozoal AgentsArtemisininsCommunicable Disease ControlCommunicable DiseasesNobel PrizeGlobal HealthHistory, 21st CenturyHumansIvermectinAnti-Infective AgentsAntiprotozoal AgentsartemisininArtemisininsavermectinIvermectin

Identifiers

PMID26708575
PMCPMC4692067
OpenAlexW2205504926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.